Schering hit by currency woes and lower prices:
This article was originally published in Clinica
Increased sales in volume terms at German company Schering's diagnostics division were not enough to compensate for lower prices and currency effects in the first half of 1998. Diagnostic sales fell 4% to DM737 million ($416 million), with sales of X-ray contrast media fell 1% to DM549 million. Sales of MRI products fell 13% to DM184 million, largely due to stock reductions by US partner, Abbott Laboratories. The Berlin-based company's total sales increased 4% to DM3,216 million, while net income rose 8% to DM307 million.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.